Ausgabe 3/2022
Inhalt (15 Artikel)
Effect of Vitamin D Serum Levels and Supplementation on Atopic Dermatitis: A Systematic Review and Meta-analysis
Jing Chun Ng, Yik Weng Yew
Cutaneous Manifestations of SARS-CoV-2 Infection
Thy Huynh, Xavier Sanchez-Flores, Judy Yau, Jennifer T. Huang
Economic Burden of Chronic Hand Eczema: A Review
April Armstrong, Julie Hahn-Pedersen, Chris Bartlett, Julie Glanville, Jacob P. Thyssen
New Practical Aspects of Sweet Syndrome
Tejas P. Joshi, Sarah K. Friske, David A. Hsiou, Madeleine Duvic
Patient and Public Involvement in Dermatology Research: A Review
Megan Heague, Chandrima Ray, Joanne Bowers, Jonathan Guckian, Bernd W. M. Arents, Alison Layton
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma
Francesca Aroldi, Mark R. Middleton
A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions
Laura Del Regno, Silvia Catapano, Alessandro Di Stefani, Simone Cappilli, Ketty Peris
Correction to: A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions
Laura Del Regno, Silvia Catapano, Alessandro Di Stefani, Simone Cappilli, Ketty Peris
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
Robert Bissonnette, Robert S. Call, Tooraj Raoof, Zhaoyin Zhu, Swamy Yeleswaram, Xiaohua Gong, Mark Lee
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
Andrew Blauvelt, Emma Guttman-Yassky, Amy S. Paller, Eric L. Simpson, Michael J. Cork, Jamie Weisman, John Browning, Weily Soong, Xian Sun, Zhen Chen, Matthew P. Kosloski, Mohamed A. Kamal, Dimittri Delevry, Chien-Chia Chuang, John T. O’Malley, Ashish Bansal
Determinants and Effectiveness of BNT162b2 mRNA Vaccination Among Patients with Atopic Dermatitis: A Population-Based Study
Khalaf Kridin, Yochai Schonmann, Erez Onn, Dana Tzur Bitan, Orly Weinstein, Arnon D. Cohen
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck, Mette Deleuran, Robert Bissonnette, Marjolein de Bruin-Weller, Ryszard Galus, Takeshi Nakahara, Seong Jun Seo, Faisal A. Khokhar, Jignesh Vakil, Jing Xiao, Ainara Rodriguez Marco, Noah A. Levit, John T. O’Malley, Arsalan Shabbir
Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
Sheridan M. Hoy
Lessons Learned from Orthopedics: A Call to Action for More Rigorous Platelet-Rich Plasma Hair Loss Clinical Trials
Shari R. Lipner, Julianne M. Falotico
Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
Ellen J. Kim, Joan Guitart, Christiane Querfeld, Michael Girardi, Amy Musiek, Oleg E. Akilov, James T. Angello, William L. Bailey, Larisa J. Geskin